Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.

All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Engineered regulatory T Cells for the treatment of GVHD and inflammatory diseases

  • A novel cell based therapy to combat disordered inflammation. Using a novel method, CD4+ and CD8+ regulatory T cells have been engineered to over express both FOXP3 and Helios without suppression of either product. Efficacy of the eTregs has been shown in vitro and in a humanized model of graft versus host disease (GVHD)
  • Benefit

    • The CD4+ and CD8+ eTregs exhibit stable expression, with about 98% of FOXP3+Helios+ cells retaining high FOXP3 and Helios expression 21 days post-transduction and 12 days in vivo in mice
    • Can separate CD4+ and CD8+ cells if desired
    • The novel method produces larger quantities of eTregs more rapidly by eliminating the need to isolate and expand populations of naturally occurring Tregs
    • First reported generation of CD8+ Tregs with suppressive activity

    Market Application

    • Biologic for the treatment of GVHD in organ and stem cell transplant patients
    • Biologic for the treatment of diseases in which it is desirable to reduce inflammatory immune responses. Examples would include type I diabetes, multiple sclerosis, allograft/transplant rejection, inflammatory bowel disease, lupus, rheumatoid arthritis, and other chronic inflammatory diseases


    Co-expression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells. A. Seng, et al; Blood Advances, Vol 4 (7), 1325-1339

Additional Details


Childrens Mercy Hospital and Kansas University

Intellectual Property Protection

Patent Issued

Interested? Request More Information